Medicinal cannabis in palliative care

Palliative care focuses on comfort, dignity and quality of life for people with serious or life-limiting illness. In that context, the usual emphasis on cure gives way to symptom relief, and the risk-benefit calculation can look different. Medicinal cannabis is sometimes considered here — but it's important to be honest about both its potential and the limits of the evidence.

What palliative patients hope it will help

Patients and families often turn to cannabis hoping it will ease a cluster of distressing symptoms common in advanced illness: pain, nausea, poor appetite, anxiety and sleeplessness. Some report meaningful relief across these symptoms.

A New Zealand-led systematic review (from Wellington researchers) examined 52 studies of cannabinoids in palliative care. It found benefits reported across a range of symptoms — but rated the quality of that evidence as "very low" or "low," meaning no firm recommendations could be made. In short: there are encouraging reports, but the rigorous evidence to back them is not yet there.

Where the evidence is firmer

Two palliative-relevant uses rest on stronger ground:

• Chemotherapy-induced nausea and vomiting. THC-based products have good (even "conclusive," per the US National Academies) evidence for refractory nausea, generally as a second- or third-line add-on after standard antiemetics — though those trials predate the newest antinausea drugs.
• MS spasticity, relevant to some neurological patients, has moderate evidence for patient-reported improvement (Sativex is the approved product).

By contrast, the hope that cannabis reliably stimulates appetite and reverses weight loss in cancer is not well supported — the best trial in cancer cachexia found no benefit over placebo. It's a kindness to set expectations accordingly.

Special considerations at end of life

Palliative patients are often frail, elderly and taking many medicines, which raises the importance of caution:

• Heightened side-effect risk. Dizziness, sedation and confusion can be more pronounced and more consequential in frail patients.
• Interactions. Cannabis adds to the sedation of opioids and benzodiazepines — common in palliative care — and CBD can affect how other drugs are metabolised. This needs careful coordination with the palliative team.
• Goals of care. When comfort is the priority, some side effects that would matter in a healthier person may be acceptable trade-offs. These are individual decisions, made with the patient, family and clinical team.

Because of all this, cannabis in palliative care is best used adjunctively and individually, integrated with the existing symptom-management plan rather than bolted on independently.

Practical guidance for families

• Work with the palliative team. Don't introduce cannabis in isolation; the team is managing a delicate balance of medicines.
• Be clear about goals. Is the aim better sleep, less nausea, calmer anxiety, more comfort? Different goals point to different products and doses.
• Manage expectations honestly. Cannabis may help with comfort, but it is not a cure and the evidence for many palliative uses is weak.
• Start low and watch closely, given the heightened vulnerability of these patients.
• Coordinate access. Hospice and palliative services can advise on whether and how cannabis fits a particular patient's care.

Routes of administration in palliative settings

How a product is taken matters especially in palliative care, where patients may have difficulty swallowing, fluctuating symptoms, or a need for rapid relief. Oromucosal sprays and sublingual drops can be useful when swallowing is hard and offer a faster onset than swallowed oils. Vaporised products act quickly, which can suit breakthrough symptoms, though they require the patient to be able to inhale effectively. Swallowed oils and capsules are slow but long-lasting. The palliative team can help match the route to the patient's abilities and the symptom being targeted — and can adjust as a patient's condition changes.

The emotional dimension

For patients and families facing serious illness, cannabis can carry hope, and that hope is human and understandable. A compassionate clinical conversation holds two things at once: respect for that hope, and honesty about what the medicine can and can't do. Overpromising risks disappointment and, worse, can divert energy from approaches that would genuinely help. Framing cannabis as one possible tool for comfort — to be trialled carefully and stopped if it doesn't help — keeps expectations grounded while honouring the patient's wishes. Hospice and palliative services are well placed to support both the clinical and the emotional sides of these decisions.

The bottom line

In palliative care, medicinal cannabis can have a genuine, if modest, role as part of a broader comfort-focused plan — particularly for nausea, and sometimes for pain, anxiety and sleep. But the evidence for many of its hoped-for benefits is low-quality, frail patients are more vulnerable to side effects and interactions, and it works best woven carefully into the existing care. Used thoughtfully, with realistic expectations and the palliative team involved, it can contribute to comfort and quality of life when those matter most.

Last reviewed 7 September 2026 — education, not medical advice. Sources: Journal of Pain and Symptom Management 2022 — palliative cannabinoids review00760-6/fulltext); US National Academies 2017.